- Type of startup : Life Sciences
- Date of entry : 07/07/2022
- Associated laboratory(ies) : INSERM UMR 1091 UCA
VTX is developing a non-cytotoxic, differentiating anti-tumour therapeutic strategy that neutralises the cancer stem cells responsible for tumour initiation, progression and resistance to treatment.
